Coagulation inhibitor replacement during sepsis: Useless?

Critical Care Medicine

Volumn 28, Issue 9 SUPPL., 2000, Pages

  Hoffman, J N ^a   Faist, E ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Coagulation; Microcirculation; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; CELL ADHESION MOLECULE; HEPARIN; RECOMBINANT HIRUDIN; TISSUE FACTOR PATHWAY INHIBITOR;

ALLERGIC REACTION; BLEEDING DISORDER; BLOOD CLOTTING; CELL ACTIVATION; CELL INTERACTION; CLINICAL TRIAL; CYTOKINE RELEASE; FIBRIN DEPOSITION; HUMAN; MEDIATOR RELEASE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 0033810748     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200009001-00016     Document Type: Review

References (44)

1. Uncontrolled plasma proteolysis: A major threat to the septicemic patient
2. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome
3. Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients
4. Coagulation, fibrinolysis, and kallikrein systems in sepsis: Relation to outcome
5. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies
6. Antithrombin levels related to infections and outcome
7. Sepsis and coagulation: An important link
8. Activation of coagulation after administration of tumor necrosis factor to normal subjects
9. Pathogenesis of disseminated intravascular coagulation in sepsis
10. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome
11. Coagulation disorders in septic shock
12. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
13. Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations
14. The contact system contributes to hypotension but not to disseminated intravascular coagulation in lethal bacteremia
15. The proinflammatory cytokine response to coagulation and endotoxin in whole blood
16. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
17. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
18. Comparison of the early dynamics of coagulation activation after injection of endotoxin and tumor necrosis factor in healthy humans
19. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
20. Vascular effects of thrombin
21. Septic shock
22. Circulating ICAM-1 is increased in septic shock
23. Circulating adhesion molecules in disease
24. Mikrozirkulation und Hamostase bei entzundlichen Prozessen
25. The microcirculation during endotoxinemia
26. The microcirculation and inflammation: Modulation of leukocyte-endothelial cell interaction
27. The pathogenesis of sepsis
28. Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1
29. Microvascular perfusion is impaired in a rat model of normotensive sepsis
30. Mediators of endotoxin-induced leukocyte adhesion in mesenteric postcapillary venules
31. Differential roles of selectins and the alpha-integrin in acute, subacute, and chronic leukocyte recruitment in vivo
32. Multiple-organ failure
33. Endotoxemia and neutrophil infiltration in vivo
34. Antithrombin replacement in DIC and MOF
35. Role of leukocytes in the activation of intravascular coagulation in patients with septicemia
36. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin
37. The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model
38. Substitution of antithrombin III in shock and DIC: A randomized study
39. Coagulation inhibitor substitution during sepsis
40. Antithrombin III (AT III) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled, double blind, randomized, multicenter study
41. New biological concepts on coagulation inhibitors
42. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway
43. Effect of antithrombin III supplementation on inflammatory immune response in patients with severe sepsis
44. The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte-endothelial cell interaction and microvascular perfusion failure